The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Programming the magnitude and persistence of antibody responses with innate immunity
Open accessAbstract
Many successful vaccines induce persistent antibody responses that can last a lifetime. The mechanisms by which they do so remain unclear, but emerging evidence indicates that they activate dendritic cells via Toll-like receptors (TLRs). For example, the yellow fever vaccine YF-17D, one of the most successful empiric vaccines ever developed, activates dendritic cells via multiple TLRs to stimulate proinflammatory cytokines. Triggering specific combinations of TLRs in dendritic cells can induce synergistic production of cytokines, which results in enhanced T-cell responses, but its impact on antibody responses remain unknown. Learning the critical parameters of innate immunity that program such antibody responses remains a major challenge in vaccinology. Here we demonstrate that immunization of mice with synthetic nanoparticles containing antigens plus ligands that signal through TLR4 and TLR7 induces synergistic increases in antigen-specific, neutralizing antibodies compared to immunization with nanoparticles containing antigens plus a single TLR ligand. Consistent with this there was enhanced persistence of germinal centres and of plasma-cell responses, which persisted in the lymph nodes for >1.5 years. Surprisingly, there was no enhancement of the early short-lived plasma-cell response relative to that observed with single TLR ligands. Molecular profiling of activated B cells, isolated 7 days after immunization, indicated that there was early programming towards B-cell memory. Antibody responses were dependent on direct triggering of both TLRs on B cells and dendritic cells, as well as on T-cell help. Immunization protected completely against lethal avian and swine influenza virus strains in mice, and induced robust immunity against pandemic H1N1 influenza in rhesus macaques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & MUENCH, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 19,926
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
A simple method of estimating 50 per cent end points
Muench, H. (1938) · Medical Entomology and Zoology · Cited by 8,376
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 3,929
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · cited 1×
“vector RIG 0 2 4 6 vector KLm (1-1012) KLs (1-549) KLsss (34-549)”
Seth, R. B., Sun, L., Ea, C.-K., & Chen, Z. J. (2005) · Cell · doi:10.1016/j.cell.2005.08.012 · Cited by 3,329
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K. J., Takeuchi, O., & Akira, S. (2005) · Nature Immunology · doi:10.1038/ni1243 · Cited by 2,562 · cited 1×
“vector RIG 0 2 4 6 vector KLm (1-1012) KLs (1-549) KLsss (34-549)”
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., & Tschopp, J. (2005) · Nature · doi:10.1038/nature04193 · Cited by 2,401
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596
T follicular helper cell biology: a decade of discovery and diseases
Crotty, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.011 · Cited by 1,591
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Self-citationImmunological mechanisms of vaccination
Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,089
Self-citationGerminal Center B Cell Dynamics
Mesin, L., Ersching, J., & Victora, G. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.001 · Cited by 994
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Yang, R., Xu, J., Xu, L., Sun, X., Chen, Q., Zhao, Y., Peng, R., & Liu, Z. (2018) · ACS Nano · doi:10.1021/acsnano.7b09041 · Cited by 698
Xu, J., Xu, L., Wang, C., Yang, R., Zhuang, Q., Han, X., Dong, Z., Zhu, W., Peng, R., & Liu, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b00715 · Cited by 695
Kurosaki, T., Kometani, K., & Ise, W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3802 · Cited by 691
Elmowafy, E. M., Tiboni, M., & Soliman, M. E. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00439-x · Cited by 621
Managing diabetes with nanomedicine: challenges and opportunities
Veiseh, O., Tang, B. C., Whitehead, K. A., Anderson, D. G., & Langer, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4477 · Cited by 613
Kraft, J. C., Freeling, J. P., Wang, Z., & Ho, R. J. Y. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23773 · Cited by 606
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Yue, W., Chen, L., Yu, L., Zhou, B., Yin, H., Ren, W., Liu, C., Guo, L., Zhang, Y., Sun, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09760-3 · Cited by 590
Innate Immune Function by Toll-like Receptors: Distinct Responses in Newborns and the Elderly
Kollmann, T. R., Levy, O., Montgomery, R. R., & Goriely, S. (2012) · Immunity · doi:10.1016/j.immuni.2012.10.014 · Cited by 565
A Temporal Switch in the Germinal Center Determines Differential Output of Memory B and Plasma Cells
Weisel, F. J., Zuccarino-Catania, G. V., Chikina, M., & Shlomchik, M. J. (2016) · Immunity · doi:10.1016/j.immuni.2015.12.004 · Cited by 524
Oh, J. Z., Ravindran, R., Chassaing, B., Carvalho, F. A., Maddur, M. S., Bower, M., Hakimpour, P., Gill, K. P., Nakaya, H. I., Yarovinsky, F., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.009 · Cited by 541
“signaling on B cells is important for mediating antibody responses to certain adjuvanted vaccines (Kasturi et al., 2011; Pasare and Medzhitov, 2005).”
BackgroundSelf-citationModulating immunity as a therapy for bacterial infections
Hancock, R. E. W., Nijnik, A., & Philpott, D. J. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2745 · Cited by 535
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 467
Molecular programming of B cell memory
McHeyzer-Williams, M., Okitsu, S., Wang, N., & McHeyzer-Williams, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3128 · Cited by 449
Lynn, G. M., Laga, R., Darrah, P. A., Ishizuka, A. S., Balaci, A. J., Dulcey, A. E., Pechar, M., Pola, R., Gerner, M. Y., Yamamoto, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3371 · Cited by 440
Follicular dendritic cells: dynamic antigen libraries
Heesters, B. A., Myers, R. C., & Carroll, M. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3689 · Cited by 429
Tam, H. H., Melo, M. B., Kang, M., Pelet, J. M., Ruda, V. M., Foley, M. H., Hu, J. K., Kumari, S., Crampton, J., Baldeon, A. D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606050113 · Cited by 425
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Engineering Nano‐ and Microparticles to Tune Immunity
Moon, J. J., Huang, B., & Irvine, D. J. (2012) · Advanced Materials · doi:10.1002/adma.201200446 · Cited by 404
Tailoring Materials for Modulation of Macrophage Fate
Li, J., Jiang, X., Li, H., Gelinsky, M., & Gu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202004172 · Cited by 403
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination
Desmet, C. J., & Ishii, K. J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3247 · Cited by 392
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Bacterial outer membrane vesicles as a platform for biomedical applications: An update
Li, M., Zhou, H., Yang, C., Wu, Y., Zhou, X., Liu, H., & Wang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.031 · Cited by 370
CXCL13 is a plasma biomarker of germinal center activity
Havenar-Daughton, C., Lindqvist, M., Heit, A., Wu, J. E., Reiss, S. M., Kendric, K., Bélanger, S., Kasturi, S. P., Landais, E., Akondy, R. S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520112113 · Cited by 353
Self-citationNovel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
Nanoparticle approaches against bacterial infections
Gao, W., Thamphiwatana, S., Angsantikul, P., & Zhang, L. (2014) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1282 · Cited by 347
Sage, P. T., & Sharpe, A. H. (2016) · Immunological Reviews · doi:10.1111/imr.12411 · Cited by 330
Watson, D. S., Endsley, A. N., & Huang, L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.070 · Cited by 322
Extrafollicular responses in humans and SLE
Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E., & Sanz, I. (2019) · Immunological Reviews · doi:10.1111/imr.12741 · Cited by 317
Wilson, J. T., Keller, S., Manganiello, M. J., Cheng, C., Lee, C.-C., Opara, C., Convertine, A., & Stayton, P. S. (2013) · ACS Nano · doi:10.1021/nn305466z · Cited by 317
Designing spatial and temporal control of vaccine responses
Roth, G. A., Picece, V. C. T. M., Ou, B. S., Luo, W., Pulendran, B., & Appel, E. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00372-2 · Cited by 316
Self-citationMoon, J. J., Suh, H., Li, A. V., Ockenhouse, C. F., Yadava, A., & Irvine, D. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112648109 · Cited by 312
Yeste, A., Nadeau, M., Burns, E. J., Weiner, H. L., & Quintana, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120611109 · Cited by 302
Beyond pattern recognition: five immune checkpoints for scaling the microbial threat
Blander, J. M., & Sander, L. E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3167 · Cited by 290
A DNA Nanostructure Platform for Directed Assembly of Synthetic Vaccines
Liu, X., Xu, Y., Yu, T., Clifford, C., Liu, Y., Yan, H., & Chang, Y. (2012) · Nano Letters · doi:10.1021/nl301877k · Cited by 289
Lynn, D. J., Benson, S. C., Lynn, M. A., & Pulendran, B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00554-7 · Cited by 289
Self-citationAdjuvants: Classification,Modus Operandi, and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 287
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Ni, Q., Zhang, F., Liu, Y., Wang, Z., Yu, G., Liang, B., Niu, G., Su, T., Zhu, G., Lu, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaw6071 · Cited by 281
Liu, W.-L., Zou, M.-Z., Liu, T., Zeng, J.-Y., Li, X., Yu, W.-Y., Li, C.-X., Ye, J.-J., Song, W., Feng, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11157-1 · Cited by 272
Rosalia, R. A., Cruz, L. J., van Duikeren, S., Tromp, A. T., Silva, A. L., Jiskoot, W., de Gruijl, T., Löwik, C., Oostendorp, J., van der Burg, S. H., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.053 · Cited by 269
Kemp, C., Mueller, S., Goto, A., Barbier, V., Paro, S., Bonnay, F., Dostert, C., Troxler, L., Hetru, C., Meignin, C., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1102486 · Cited by 264
Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery
Ho, W., Gao, M., Li, F., Li, Z., Zhang, X., & Xu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001812 · Cited by 261
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
Vasilakos, J. P., & Tomai, M. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811208 · Cited by 254
Sonodynamic therapy-derived multimodal synergistic cancer therapy
Xu, M., Zhou, L., Zheng, L., Zhou, Q., Liu, K., Mao, Y., & Song, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.037 · Cited by 211
de Alwis, R., Gan, E. S., Chen, S., Leong, Y. S., Tan, H. C., Zhang, S. L., Yau, C., Low, J. G. H., Kalimuddin, S., Matsuda, D., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.001 · Cited by 191
“129 The innate immune response, particularly the type-I interferon (IFN) response has previously 130 been shown to be associated with vaccine immunogenicity following yellow fever 131 vaccination [11, 12, 18].”
BackgroundEliciting B cell immunity against infectious diseases using nanovaccines
Singh, A. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00790-3 · Cited by 169
Kwissa, M., Nakaya, H. I., Oluoch, H., & Pulendran, B. (2012) · Blood · doi:10.1182/blood-2011-10-388579 · Cited by 132
Self-citationRNA Mediated toll-like receptor stimulation in health and disease
Dalpke, A. H., & Helm, M. (2012) · RNA Biology · doi:10.4161/rna.20206 · Cited by 113
Farrera, C., & Fadeel, B. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.007 · Cited by 92
Van Hoeven, N., Fox, C. B., Granger, B., Evers, T., Joshi, S. W., Nana, G. I., Evans, S. C., Lin, S., Liang, H., Liang, L., et al. (2017) · Scientific Reports · doi:10.1038/srep46426 · Cited by 87
Contribution of Toll-like receptor signaling to germinal center antibody responses
DeFranco, A. L., Rookhuizen, D. C., & Hou, B. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01115.x · Cited by 74
Shen, L., Tenzer, S., Storck, W., Hobernik, D., Raker, V. K., Fischer, K., Decker, S., Dzionek, A., Krauthäuser, S., Diken, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.049 · Cited by 74
Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants
Miyaji, E. N., Carvalho, E., Oliveira, M. L. S., Raw, I., & Ho, P. L. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500064 · Cited by 66
“Therefore, new trends in vaccine developments include the use of new adjuvants (PAMPs or DAMPs) based on new PRR agonists as well as the combination of these adjuvants, aiming at the programming of the magnitude and persistence of the desired immune response (55).”
Background
Metadata
- Authors
- Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., Villinger, F., Murthy, N., Steel, J., Jacob, J., Hogan, R. J., García-Sastre, A., Compans, R., & Pulendran, B.
- Venue
- Nature
- Published
- 2011-02
- Volume
- 470
- Issue
- 7335
- Pages
- 543-547
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2045465609
- Cited by
- 975
- References
- 83
- FWCI
- 35.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.